© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Revolutionizing Atopic Dermatitis (RAD)
RAD is where your goal to improve patients’ lives converges with meaningful discussions and groundbreaking concepts in atopic dermatitis. At this dynamic gathering, evidence drives conversations and strategies that matter are conceived, giving you an unparalleled platform to expand your skills. This year, we’re turning up the energy in Nashville. Get ready to experience Nashville’s vibrant culture and iconic music scene, right here at RAD!
Atopic dermatitis is not just "another rash on the schedule. It could the the reason that patient doesn't leave the house."
RAD 2025: Multidisciplinary collaboration at disease-specific meetings drives clinical and therapeutic progress in AD, Dr Yu told Patient Care.
Dermatologists aren't trained in mental health but once in practice they need to have a deep appreciation for the emotional impact of diseases like AD and a low bar for mental health referral.
At RAD 2025, Dr Yu shared hopes for more real-world data and targeted treatment approaches for chronic hand eczema.
RAD 2025: Yale dermatologist Mona Shahriari, MD, urged primary care clinicians to refer patients with AD who don't improve to prevent cumulative emotional burden.
RAD 2025: Expert insights on the psychosocial burden of AD, flexible dosing, and cross-specialty collaboration in pediatric care.
RAD 2025: Johann Gudjonsson, MD, PhD, on investigational AD treatments, including anti–IL-31 receptor antibodies, anti–IL-13 treatments, IL-4 receptor blockers, JAK inhibitors, and new topical agents.
RAD 2025: Brad Glick, DO, MPH, discusses the intensity of TSW symptoms and cautions against assuming there is mental health disturbance at work.
Johann Gudjonsson, MD, discusses how OX-40/OX-40L signaling drives immune activation in AD and its emerging role as a genetic and therapeutic target.
The literature on topical steroid withdrawal syndrome is scant, Glick says; we're learning more about it, but we need more research to help our patients.